Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today
announced that members of Rocket’s executive team will participate in the following upcoming investor conferences:
- Citi’s 13th Annual Biotech Conference on September 6, 2018 in Boston, MA
- Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018 at 5:15 p.m.
Eastern Time in New York, NY
A live audio webcast of the Morgan Stanley fireside chat will be available on the Investors section of the company’s website,
www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on
developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development
approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.
Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic
disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders
are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant
Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For
more information about Rocket, please visit
www.rocketpharma.com.
Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005090/en/